#Paris #France #Echosens #Romain Baujard #Dominique Legros

Romain Baujard Takes the Helm at Echosens as CEO

Echosens, a global leader in non-invasive diagnostic solutions, has announced the appointment of Romain Baujard as their new Chief Executive Officer, effective May 1, 2026. This significant change comes as the current CEO, Dominique Legros, prepares to retire after a successful tenure that began in 2019. Under Legros’ leadership, Echosens experienced robust global expansion and increased adoption of its groundbreaking technology.

A Strategic Move for Echosens

As Echosens aims to solidify its position in the healthcare sector, the choice of Baujard is strategic. He joined Echosens back in 2015, quickly rising through the ranks to become the Vice President of the Pharmaceutical Division. His diverse experience in strategic and operational leadership makes him well-suited to navigate the challenges and opportunities ahead. Baujard has not only managed global marketing strategies but has also established crucial partnerships with major pharmaceutical companies, further enhancing Echosens’ influence in the domains of liver health and emerging cardiometabolic therapies.

In his new role, Baujard emphasizes the critical importance of integrating liver health evaluation into routine care, noting how it is becoming increasingly essential in assessing and treating patients effectively. He stated, "Our opportunity lies in incorporating liver assessment as a fundamental part of large-scale routine care."

A Focus on Liver Health in Healthcare

With rising global prevalence of metabolic diseases and fast-paced innovations in treatment, the healthcare landscape is evolving. Echosens recognizes the unique position it holds in addressing these challenges, particularly in early detection, risk stratification, and long-term disease management. Baujard's appointment signals a commitment to expanding the reach and impact of Echosens' technologies, especially beyond traditional medical specialties.

"I am honored to take on this responsibility during a pivotal moment for Echosens, as we look to accelerate innovation in cardiometabolic care," he affirmed. The commitment to enhancing digital tools, data capabilities, and artificial intelligence is paramount for driving timely detection and effective risk management, he added.

Legacy of Dominique Legros

Dominique Legros leaves behind a legacy of substantial growth and transformation at Echosens. His leadership has helped position the company as a global reference for non-invasive liver assessment, expanding the use of FibroScan® into fields beyond hepatology and gastroenterology, such as diabetology, endocrinology, and primary care. This shift showcases the expanding recognition of liver health as a cornerstone in comprehensive metabolic management.

Reflecting on his tenure, Legros commented, "Leading Echosens has been a privilege. Our aim has always been to empower healthcare professionals to make better clinical decisions. I take pride in our achievements in spreading the message of liver health as vital in healthcare systems worldwide."

He expresses confidence in Baujard, believing he is the perfect leader to guide Echosens into its next growth phase.

Future Prospects

In collaboration with Inner Mongolia FuRui Medical Science, a high-tech enterprise focused on long-term liver disease management, and Astorg, a premier pan-European private equity firm, Echosens is positioning itself for continued growth. The partnership promises to bolster Echosens’ capabilities in liver health, aligning with the evolving needs of the healthcare sector.

Echosens is committed to expanding access to its technologies and improving medical professional support. As the company embarks on this new chapter under Romain Baujard’s leadership, the opportunity to innovate and respond to growing healthcare demands looks promising.

For more information about Echosens and its commitment to enhancing liver health as a vital indicator of cardiometabolic care, visit their official website or refer to their latest updates.